期刊文献+

腰椎间盘髓核组织中miR-200c、TrkB表达变化及其与退变程度的相关性 被引量:3

下载PDF
导出
摘要 目的观察微小RNA-200c(miR-200c)与酪氨酸激酶受体B(Trk B)腰椎间盘髓核组织中的表达变化,并探讨其与腰椎间盘髓核退变程度的相关性。方法收集腰椎间盘髓核组织标本60例,用Pfirmlann分级对髓核退变程度进行分级,Ⅱ、Ⅲ、Ⅳ级各20例。采用细胞衰老β-半乳糖苷酶实验检测不同分级髓核组织中衰老髓核细胞百分比,RT-PCR技术检测髓核组织中miR-200c、Trk B mRNA表达,Western blotting技术检测髓核组织中Trk B蛋白表达,采用Pearson相关分析miR-200c、Trk B与衰老髓核细胞的关系。结果 PfirmlannⅡ、Ⅲ、Ⅳ级髓核组织中衰老髓核细胞百分比、miR-200c相对表达量、Trk B mRNA及蛋白相对表达量两两比较,P均<0.05。miR-200c mRNA与Trk B mRNA相对表达量呈负相关(r=-0.71,P<0.05),miR-200c mRNA相对表达量与衰老髓核细胞百分比呈正相关(r=0.75,P<0.05),Trk B mRNA相对表达量与衰老髓核细胞百分比呈负相关(r=-0.70,P<0.05)。结论腰椎间盘髓核退变程度越高,miR-200c表达越高,Trk B mRNA表达越低;miR-200c可能通过下调Trk B表达参与腰椎间盘髓核组织的退变过程。
出处 《山东医药》 CAS 北大核心 2017年第21期79-81,共3页 Shandong Medical Journal
  • 相关文献

参考文献3

二级参考文献34

  • 1Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classifi- cation of tumours of the central nervous system [ J ]. Acta Neuro- pathol, 2007,114(2) :97-109.
  • 2Yan Q, Rosenfeld RD, Matheson CR, et al. Expression of brain-de- rived neurotrophic factor protein in the adult rat central nervous sys- tem[J]. Neurosci, 1997,78(2) :431-448.
  • 3Skup M, Dwornik A, Macias M, et al. Long-term locomotor training up-regulates TrkB (FL) receptor-like proteins, brain-derived neurot rophic factor, and neurotrophin 4 with different topographies of ex- pression in oligodendroglia and neurons in the spinal cord[ J]. Exp Neurol, 2002,176 (2) :289-307.
  • 4Almeida RD, Manads B J, Melo CV, et al. Neuroprotection by BD- NF against glutamate induced apoptotic cell death is mediated by ERK and PI3-kinase pathways [ J ]. Cell Death Diffa, 2005, 12 (10) :1329-1343.
  • 5Sugimoto T, Ikuroda H, Horii Y, et al. Signal transduction path- ways through TRK-A and TRK-B receptors in human neuroblastoma cells[J]. J Cancer Res, 2001,92(2) :152-160.
  • 6Aoyama M, Asai K, Shishikura T, et al. Human neurob lastom as with unfavorable biologies express high levels of brain-derived neuro- trophic factorm RNA and a variety of its variants[ J ]. Cancer Lett, 2001,164(1) :51-60.
  • 7Parkin D M, Bray F, Ferlay J, et al. Global cancer statis- tics, 2002[J]. CA Cancer J Clin, 2005, 55(2) :74-108.
  • 8Ajani J A. Evolving chemotherapy for advanced gastric cancer[ J ]. Oncologist, 2005, 10 ( Suppl 3) :49-58.
  • 9Shi L, Zhou Q, Wu J, et al. Efficacy of adjuvant immu- notherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer[ J ]. Cancer Immunol Immunother, 2012, 61 (12):2251-2259.
  • 10Madhavan D, Zucknick M, Wallwiener M, et al. Circu- lating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer [J]. Clin Cancer Res, 2012, 18(21 ) :5972-5982.

共引文献4

同被引文献37

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部